Skip to main content

Hyaluronidase / Pertuzumab / Trastuzumab Dosage

Medically reviewed by Drugs.com. Last updated on Jul 3, 2024.

Applies to the following strengths: 30,000 units-1200 mg-600 mg/15 mL; 20,000 units-600 mg-600 mg/10 mL

Usual Adult Dose for Breast Cancer

Initial dose: 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase subcutaneously over approximately 8 minutes
Maintenance dose: 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase subcutaneously over approximately 5 minutes every 3 weeks after the initial dose
NOTE: Patients currently receiving IV pertuzumab and trastuzumab can transition to this combination. In patients receiving IV pertuzumab and trastuzumab with less than 6 weeks since their last dose, administer this combination as a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab and every 3 weeks for subsequent administrations. In patients receiving IV pertuzumab and trastuzumab with 6 weeks or more since their last dose, administer this combination as an initial dose of 1200 mg pertuzumab/600 mg trastuzumab, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab every 3 weeks for subsequent administrations.

Neoadjuvant Treatment of Breast Cancer:


Adjuvant Treatment of Breast Cancer:

Metastatic Breast Cancer (MBC):

Uses:

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

DOSE MODIFICATIONS FOR LEFT VENTRICULAR DYSFUNCTION (LVEF):
EARLY BREAST CANCER:

METASTATIC BREAST CANCER:
NOTE: If after a repeat assessment within approximately 3 weeks, the LVEF has not improved, has declined further, and/or the patient is symptomatic, permanently discontinue therapy.

Hypersensitivity and Administration-Related Reactions:

Precautions

US BOXED WARNINGS:
CARDIOMYOPATHY:

Recommendations:
EMBRYOFETAL TOXICITY:
Recommendation:
PULMONARY TOXICITY:
Recommendations:

CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

Monitoring:
Assess left ventricular ejection fraction (LVEF) prior to initiation of therapy and at regular intervals during therapy.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.